Mayo Stephen 4

What Happened
Stephen Mayo, a director of Sarepta Therapeutics (SRPT), reported the sale of 7,239 shares on 2026-03-12 at $17.02 per share, resulting in gross proceeds of approximately $123,208. The transaction was a sale (reported as an open-market/private sale) and appears to be a routine disposition rather than a purchase.

Key Details

• Transaction date: 2026-03-12; reported on Form 4 filed 2026-03-13 (appears timely).
• Price per share: $17.02; Shares sold: 7,239; Gross proceeds: ~$123,208.
• Shares owned after transaction: Not disclosed in the supplied summary.
• Footnote F1: Sale executed to generate cash to pay taxes due on the vesting of certain restricted stock units (RSUs). This is a tax-withholding-related sale (routine).
• Transaction code: S (Sale). No 10b5-1 plan or late filing flag indicated in the provided data.

Context
Sales to cover tax withholding on vested RSUs are common and typically reflect tax-management activity rather than a directional view on the company’s stock. For investors, purchases by insiders tend to be more informative about bullish conviction; this reported sale appears procedural per the footnote.